Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06831123 · ClinicalTrials.gov registry record · Phase 1
Pathways 2 Success
A Phase 1 study of Conduct Disorder and Oppositional Defiant Disorder, sponsored by University of Minnesota.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT06831123: Recruiting Phase 1 study of Conduct Disorder and Oppositional Defiant Disorder, sponsored by University of Minnesota.
NCT06831123 is a Phase 1 study of Conduct Disorder and Oppositional Defiant Disorder that is actively recruiting participants, run by University of Minnesota. The registered enrollment target is 120 participants, below the 698-participant average among 11 other Conduct Disorder trials with a reported enrollment target (83% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06831123, a Phase 1 study of Conduct Disorder and Oppositional Defiant Disorder, is actively recruiting participants, sponsored by University of Minnesota.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This study involves a 3-arm randomized controlled trial designed to investigate the feasibility and acceptability of three preventive interventions designed to reduce risk for escalations in adolescent conduct problems. High school students identified to be at risk for conduct problems will be randomly assigned to one of three intervention options, including a mindfulness-based program, a mindfulness-based program augmented by a new mobile app, and a life skills program. Assessments related to intervention outcomes will be completed by adolescents, parents/guardians, and teachers at baseline, 2 weeks post-intervention, and at a 3-month follow-up.
Primary Outcome
A rating scale used to evaluate the number of times in the past month adolescents have committed 17 different antisocial acts. A rating scale used to evaluate the number of times in the past month adolescents have committed 17 different antisocial acts. Scores range from 0 to 17, with higher scores reflecting greater engagement in delinquent behaviors.
Conditions Studied
Interventions
- BEHAVIORAL L2B
- BEHAVIORAL L2B + App
- BEHAVIORAL skills for success
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-03-12 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
What NCT06831123 shows while recruiting
NCT06831123 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 698-participant average among 11 other Conduct Disorder trials with a reported enrollment target (83% lower).
The record links to 2 conditions, with Conduct Disorder appearing as the primary indexed condition, and to 3 interventions - of which L2B is the first listed.
NCT06831123 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT06831123 about?
NCT06831123 is a clinical study titled "Pathways 2 Success". This study involves a 3-arm randomized controlled trial designed to investigate the feasibility and acceptability of three preventive interventions designed to reduce risk for escalations in adolescent conduct problems. High school students identified to be at risk for conduct problems will be rando...
What is the current status of trial NCT06831123?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2025-03-12. Estimated completion is 2027-02-28.
What conditions does trial NCT06831123 study?
This clinical trial studies the following conditions: Conduct Disorder, Oppositional Defiant Disorder.
What interventions are being tested in trial NCT06831123?
The interventions under investigation include: L2B (BEHAVIORAL), L2B + App (BEHAVIORAL), skills for success (BEHAVIORAL).
Who is sponsoring clinical trial NCT06831123?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06831123 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Conduct Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06831123's enrollment target sits among peer trials
120 8th of 11 higher than 4 of 11 other Conduct Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Conduct Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Developing Brain, Impulsivity and Compulsivity
RECRUITING
-
Digital Single Session Intervention for Youth Mental Health
RECRUITING · NA
-
Multisite Prevention of Conduct Problems (Fast Track)
ACTIVE NOT RECRUITING · NA
-
Integrated Smart Speaker Promoting Positive Parenting Among Caregivers of Youth With Challenging Behaviors
COMPLETED · NA
-
Behavioral Treatment for Children With Conduct Problems and Callous-Unemotional Traits
COMPLETED · NA
-
Randomized Control Trial of an Animal-Assisted Intervention With Adjudicated Youth
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI